Europe has become something of a testing ground for what psychedelic therapies might look like beyond the confines of clinical trials. While conventional approval pathways remain central to long-term healthcare integration, several countries have developed alternative access models, which in 2025 came to include Germany, Norway, and the Czech Republic.Here, Helena Aicher…
